Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin A Post published:August 13, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: UK Patent Examiner Questions Compass Patent; Canadians Overwhelmingly Support Psilocybin Policy Reform; No Data Protection for Spravato in Canada Post published:August 6, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MindMed Initiates DMT Trial; COMPASS Appoints CMO; Field Trip Lists on NASDAQ Post published:July 30, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Field Trip Set to List on Nasdaq; Cybin to List on NYSE American Post published:July 24, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Third Psychedelics ETF Expected to Launch; Tracking Psychedelic Drug Policy Reform; One Direction for atai Post published:July 16, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Compass Announces New Collaboration; MindMed Partners with Real-World Data Provider; Yale Researchers Show Psilocybin Increases Nueronal Connections Post published:July 9, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Harvard Law School Launches Psychedelics Project; California Decrim. Bill Clears Latest Hurdle; LSD for Food Allergies? Post published:July 2, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Ex-FDA Psychiatry Director Joins Cybin as Advisor; Texas Approves Psychedelics Studies; and more… Post published:June 25, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: atai IPOs on Nasdaq; Cybin to Target Anxiety Indications; Next Steps for California Decrim. Bill Post published:June 18, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation Post published:June 11, 2021 Post category:Psychedelic Bulletin